Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind randomized trial of AK001 plus intranasal steroid in moderate to severe nasal polyposis
2016-000460-42Phase 2Completed
- Sponsor
- Allakos Inc.
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AK001 in chronic rhinosinusitis with nasal polyps (CRSwNP) (3 arms), sponsored by Allakos Inc. Primary endpoint: Total Polyp Score (TPS) change. Started Mar 2016; status: completed.
02
Drugs
AK001
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on 2016-000460-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000460-42.